Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer’s Disease

Novel derivatives based on 6-methyluracil and condensed uracil, 2,4-quinazoline-2,4-dione, were synthesized with terminal meta- and para-benzoate moieties in polymethylene chains at the N atoms of the pyrimidine ring. In the synthesized compounds, the polymethylene chains were varied from having tris- to hexamethylene chains and quaternary ammonium groups; varying substituents (ester, salt, acid) at benzene ring were introduced into the chains and benzoate moieties. In vivo biological experiments demonstrated the potency of these compounds in decreasing the number of β-amyloid plaques and their suitability for the treatment of memory impairment in a transgenic model of Alzheimer’s disease.

[1]  John Z. H. Zhang,et al.  MolGpka: A Web Server for Small Molecule pKa Prediction Using a Graph-Convolutional Neural Network , 2021, J. Chem. Inf. Model..

[2]  K. Jellinger.  Neuropathology of the Alzheimer's continuum: an update. , 2020, Free neuropathology.

[3]  S. Lushchekina,et al.  Novel Acetylcholinesterase Inhibitors Based on Uracil Moiety for Possible Treatment of Alzheimer Disease , 2020, Molecules.

[4]  M. Sabbagh,et al.  Alzheimer’s Disease Drug Development Pipeline 2020 , 2020, The Journal of Prevention of Alzheimer's Disease.

[5]  N. Petrova,et al.  New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease , 2019, Neuropharmacology.

[6]  P. Meyers,et al.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke , 2018, American Journal of Neuroradiology.

[7]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[8]  P. Masson,et al.  6‐Methyluracil Derivatives as Bifunctional Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease , 2015, ChemMedChem.

[9]  R. Lane,et al.  Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value. , 2015, Journal of Alzheimer's disease : JAD.

[10]  E. Krejci,et al.  Optimal detection of cholinesterase activity in biological samples: modifications to the standard Ellman's assay. , 2014, Analytical biochemistry.

[11]  M. Rudolph,et al.  Structures of human acetylcholinesterase in complex with pharmacologically important ligands. , 2012, Journal of medicinal chemistry.

[12]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[13]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[14]  A. Nemukhin,et al.  Characterization of a complete cycle of acetylcholinesterase catalysis by ab initio QM/MM modeling , 2008, Journal of molecular modeling.

[15]  J. Rawlins,et al.  T-maze alternation in the rodent , 2006, Nature Protocols.

[16]  D. Borchelt,et al.  Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities , 2005, Neurobiology of Disease.

[17]  N. Inestrosa,et al.  Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. , 2004, The American journal of pathology.

[18]  Stephen Maren,et al.  Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. , 2002, Learning & memory.

[19]  J Andrew McCammon,et al.  Role of the catalytic triad and oxyanion hole in acetylcholinesterase catalysis: an ab initio QM/MM study. , 2002, Journal of the American Chemical Society.

[20]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[21]  Claudia Linker,et al.  Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme , 1996, Neuron.

[22]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[23]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[24]  Gwenn S. Smith.  Animal models of Alzheimer's disease: experimental cholinergic denervation , 1988, Brain Research Reviews.

[25]  K. Johnson.  An Update. , 1984, Journal of food protection.

[26]  G. Blessed,et al.  NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.

[27]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[28]  A. Cornish-Bowden.  A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. , 1974, The Biochemical journal.

[29]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[30]  E. S. Weiss.  An abridged table of probits for use in the graphic solution of the dosage-effect curve. , 1948, American journal of public health and the nation's health.